Cargando…

Utility of (18)F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer

BACKGROUND: Accurate evaluation of axillary lymph node (ALN) involvement is mandatory before treatment of primary breast cancer. The aim of this study is to compare preoperative diagnostic accuracy between positron emission tomography/computed tomography with (18)F-fluorodeoxyglucose ((18)F-FDG PET/...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Shigeto, Tsuda, Hitoshi, Asakawa, Hideki, Omata, Jiro, Fukatsu, Kazuhiko, Kondo, Nobuo, Kondo, Tadaharu, Hama, Yukihiro, Tamura, Katsumi, Ishida, Jiro, Abe, Yoshiyuki, Mochizuki, Hidetaka
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430574/
https://www.ncbi.nlm.nih.gov/pubmed/18541009
http://dx.doi.org/10.1186/1471-2407-8-165
_version_ 1782156412070133760
author Ueda, Shigeto
Tsuda, Hitoshi
Asakawa, Hideki
Omata, Jiro
Fukatsu, Kazuhiko
Kondo, Nobuo
Kondo, Tadaharu
Hama, Yukihiro
Tamura, Katsumi
Ishida, Jiro
Abe, Yoshiyuki
Mochizuki, Hidetaka
author_facet Ueda, Shigeto
Tsuda, Hitoshi
Asakawa, Hideki
Omata, Jiro
Fukatsu, Kazuhiko
Kondo, Nobuo
Kondo, Tadaharu
Hama, Yukihiro
Tamura, Katsumi
Ishida, Jiro
Abe, Yoshiyuki
Mochizuki, Hidetaka
author_sort Ueda, Shigeto
collection PubMed
description BACKGROUND: Accurate evaluation of axillary lymph node (ALN) involvement is mandatory before treatment of primary breast cancer. The aim of this study is to compare preoperative diagnostic accuracy between positron emission tomography/computed tomography with (18)F-fluorodeoxyglucose ((18)F-FDG PET/CT) and axillary ultrasonography (AUS) for detecting ALN metastasis in patients having operable breast cancer, and to assess the clinical management of axillary (18)F-FDG PET/CT for therapeutic indication of sentinel node biopsy (SNB) and preoperative systemic chemotherapy (PSC). METHODS: One hundred eighty-three patients with primary operable breast cancer were recruited. All patients underwent (18)F-FDG PET/CT and AUS followed by SNB and/or ALN dissection (ALND). Using (18)F-FDG PET/CT, we studied both a visual assessment of (18)F-FDG uptake and standardized uptake value (SUV) for axillary staging. RESULTS: In a visual assessment of (18)F-FDG PET/CT, the diagnostic accuracy of ALN metastasis was 83% with 58% in sensitivity and 95% in specificity, and when cut-off point of SUV was set at 1.8, sensitivity, specificity, and accuracy were 36, 100, and 79%, respectively. On the other hand, the diagnostic accuracy of AUS was 85% with 54% in sensitivity and 99% in specificity. By the combination of (18)F-FDG PET/CT and AUS to the axilla, the sensitivity, specificity, and accuracy were 64, 94, and 85%, respectively. If either (18)F-FDG PET uptake or AUS was positive in allixa, the probability of axillary metastasis was high; 50% (6 of 12) in (18)F-FDG PET uptake only, 80% (4 of 5) in AUS positive only, and 100% (28 of 28) in dual positive. By the combination of AUS and (18)F-FDG PET/CT, candidates of SNB were more appropriately selected. The axillary (18)F-FDG uptake was correlated with the maximum size and nuclear grade of metastatic foci (p = 0.006 and p = 0.03). CONCLUSION: The diagnostic accuracy of (18)F-FDG PET/CT was shown to be nearly equal to ultrasound, and considering their limited sensitivities, the high radiation exposure by (18)F-FDG PET/CT and also costs of the examination, it is likely that AUS will be more cost-effective in detecting massive axillary tumor burden. However, when we cannot judge the axillary staging using AUS alone, metabolic approach of (18)F-FDG PET/CT for axillary staging would enable us a much more confident diagnosis.
format Text
id pubmed-2430574
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24305742008-06-18 Utility of (18)F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer Ueda, Shigeto Tsuda, Hitoshi Asakawa, Hideki Omata, Jiro Fukatsu, Kazuhiko Kondo, Nobuo Kondo, Tadaharu Hama, Yukihiro Tamura, Katsumi Ishida, Jiro Abe, Yoshiyuki Mochizuki, Hidetaka BMC Cancer Research Article BACKGROUND: Accurate evaluation of axillary lymph node (ALN) involvement is mandatory before treatment of primary breast cancer. The aim of this study is to compare preoperative diagnostic accuracy between positron emission tomography/computed tomography with (18)F-fluorodeoxyglucose ((18)F-FDG PET/CT) and axillary ultrasonography (AUS) for detecting ALN metastasis in patients having operable breast cancer, and to assess the clinical management of axillary (18)F-FDG PET/CT for therapeutic indication of sentinel node biopsy (SNB) and preoperative systemic chemotherapy (PSC). METHODS: One hundred eighty-three patients with primary operable breast cancer were recruited. All patients underwent (18)F-FDG PET/CT and AUS followed by SNB and/or ALN dissection (ALND). Using (18)F-FDG PET/CT, we studied both a visual assessment of (18)F-FDG uptake and standardized uptake value (SUV) for axillary staging. RESULTS: In a visual assessment of (18)F-FDG PET/CT, the diagnostic accuracy of ALN metastasis was 83% with 58% in sensitivity and 95% in specificity, and when cut-off point of SUV was set at 1.8, sensitivity, specificity, and accuracy were 36, 100, and 79%, respectively. On the other hand, the diagnostic accuracy of AUS was 85% with 54% in sensitivity and 99% in specificity. By the combination of (18)F-FDG PET/CT and AUS to the axilla, the sensitivity, specificity, and accuracy were 64, 94, and 85%, respectively. If either (18)F-FDG PET uptake or AUS was positive in allixa, the probability of axillary metastasis was high; 50% (6 of 12) in (18)F-FDG PET uptake only, 80% (4 of 5) in AUS positive only, and 100% (28 of 28) in dual positive. By the combination of AUS and (18)F-FDG PET/CT, candidates of SNB were more appropriately selected. The axillary (18)F-FDG uptake was correlated with the maximum size and nuclear grade of metastatic foci (p = 0.006 and p = 0.03). CONCLUSION: The diagnostic accuracy of (18)F-FDG PET/CT was shown to be nearly equal to ultrasound, and considering their limited sensitivities, the high radiation exposure by (18)F-FDG PET/CT and also costs of the examination, it is likely that AUS will be more cost-effective in detecting massive axillary tumor burden. However, when we cannot judge the axillary staging using AUS alone, metabolic approach of (18)F-FDG PET/CT for axillary staging would enable us a much more confident diagnosis. BioMed Central 2008-06-09 /pmc/articles/PMC2430574/ /pubmed/18541009 http://dx.doi.org/10.1186/1471-2407-8-165 Text en Copyright © 2008 Ueda et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ueda, Shigeto
Tsuda, Hitoshi
Asakawa, Hideki
Omata, Jiro
Fukatsu, Kazuhiko
Kondo, Nobuo
Kondo, Tadaharu
Hama, Yukihiro
Tamura, Katsumi
Ishida, Jiro
Abe, Yoshiyuki
Mochizuki, Hidetaka
Utility of (18)F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer
title Utility of (18)F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer
title_full Utility of (18)F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer
title_fullStr Utility of (18)F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer
title_full_unstemmed Utility of (18)F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer
title_short Utility of (18)F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer
title_sort utility of (18)f-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging ((18)f-fdg pet/ct) in combination with ultrasonography for axillary staging in primary breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430574/
https://www.ncbi.nlm.nih.gov/pubmed/18541009
http://dx.doi.org/10.1186/1471-2407-8-165
work_keys_str_mv AT uedashigeto utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT tsudahitoshi utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT asakawahideki utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT omatajiro utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT fukatsukazuhiko utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT kondonobuo utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT kondotadaharu utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT hamayukihiro utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT tamurakatsumi utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT ishidajiro utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT abeyoshiyuki utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer
AT mochizukihidetaka utilityof18ffluorodeoxyglucoseemissiontomographycomputedtomographyfusionimaging18ffdgpetctincombinationwithultrasonographyforaxillarystaginginprimarybreastcancer